PhRMA says CMS proposal to make Medicare drug negotiation permanent will 'exacerbate' existing concerns

The Pharmaceutical Research and Manufacturers of America warns that the Biden administration's plan to codify Medicare drug price negotiation as a permanent program will worsen market distortions and chill innovation. CMS has proposed making the Inflation Reduction Act's negotiation framework a standing authority, beyond the initial ten drugs selected. PhRMA argues this creates long-term uncertainty for drug development and could limit future therapeutic options. For practices, the core dynamic remains: downward pressure on drug prices from Medicare negotiation may eventually influence commercial payer formularies and prior authorization rules for expensive therapies. The comment period on the proposal is ongoing; the final rule will shape the pharmaceutical landscape for years.